Emergent BioSolutions Inc. — Director's Dealing 2013

Jan 18, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2012-11-05

Reporting Person: Kramer Robert (CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-05	Common Stock	A	11531	—	Acquired	25371	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-05	Employee Stock Option (right to buy)	$14.41	A	23062	Acquired	2019-11-04	Common Stock (23062)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	856043	Indirect

Footnotes

F1: Mr. Kramer's direct holdings include restricted stock units granted under the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan and shares distributed from BioPharm, L.L.C. to Mr. Kramer through RKRAMER L.L.C.

F2: Mr. Kramer is the general manager of RKRAMER, L.L.C., which holds 21.01% of the equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 856,043 shares of Common Stock. Mr. Kramer disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 181,746 units in BioPharm L.L.C. held directly through RKRAMER L.L.C.

F3: These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F4: Exercisable in three equal installments on November 4, 2013, November 4, 2014 and November 4, 2015